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Abstract
Cancer therapeutics have achieved success in the treatment of a variety of malignancies, however, 
relapse of disease from small numbers of persistent tumor cells remains a major obstacle. Advancement of 
treatment regimens that effectively control minimal residual disease and prevent relapse would be greatly 
accelerated if sensitive and noninvasive assays were used to quantitatively assess tumor burden in animal 
models of minimal residual disease that are predictive of the human response. In vivo bioluminescence 
imaging (BLI) is an assay for the detection of small numbers of cells non-invasively and enables the 
quantification  of  tumor  growth  within  internal  organs.  Fusion  genes  that  encode  bioluminescent  and 
fluorescent reporter proteins effectively couple the powerful in vivo capabilities of BLI with the subset -
discriminating  capabilities  of  fluorescence-activated  cell  sorting  (FACS).  We  labeled  two  murine 
lymphoma cell lines with dual function reporter genes and monitored radiation and chemotherapy as well 
as immune-based strategies that employ the tumorcidal activity of ex vivo expanded CD8
+ NK-T cells. 
Using  BLI  we  were  able  to  visualize  the  entire  course  of  malignant  disease  including  engraftment, 
expansion, metastasis, response to therapy and unique patterns of relapse. We also labeled the effector 
NK-T cells and monitored their homing to the sites of tumor growth followed by tumor eradication. These 
studies reveal the efficacy of immune cell therapies and the tempo of NK-T cell trafficking in vivo. The 
complex cellular processes in bone marrow transplantation and anti-tumor immunotherapy, previously 
inaccessible to investigation, can now be revealed in real time in living animals.
Negrs@Stanford.edu
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Introduction
Radiation and chemotherapy have proven to be effective treatments for patients with a variety of 
malignant disorders, however relapse from minimal residual disease states remains a significant challenge 
to effective treatment. Following high dose chemotherapy and autologous or allogeneic bone marrow 
transplantation (BMT) nearly all patients achieve what appears to be a complete remission where disease 
is no longer detectable with available imaging techniques, biochemical or molecular assays. However, a 
significant percentage of these patients ultimately relapse indicating that malignant cells were still present, 
yet  undetectable.  The  reduced  relapse  rate  following  allogeneic,  as  compared  to  autologous,  BMT 
provides  compelling  evidence  that  minimal  residual  disease  can  be  controlled  by  immunological 
mechanisms.
1-3 The development of adoptive cellular therapies that selectively enhance GVT effects after 
allogeneic BMT may therefore significantly improve treatment outcomes.
Animal  models  that  can  be  readily  evaluated  and  that  are  predictive  of  the  human  response  are 
critically important for the advancement of more effective therapies, and for enhancing our understanding 
of cancer cell biology and immune surveillance. However, the study of animal models has been limited by 
the  difficulty  of  accurately  assessing  disease  burden  and  response  to  therapy,  especially  in  minimal 
disease. External tumor measurements, for example with calipers or by gross inspection, are limited to 
diseases at accessible sites. Biochemical and molecular assays typically require animal sacrifice and are 
complicated by the possibility of sampling artifacts. In an effort to overcome some of these limitations, a 
variety of techniques have been developed to trace cells in vivo including labeling cells with fluorescent 
dyes, bromodeoxyuridine and radioisotopes. These techniques can be hampered by cytotoxic side effects 
of the labeling procedures and limited due to dilution, and finally loss, of the marker over time as a result 
of cell division.
4 The latter problem has been, in part, overcome by recent advances in viral transduction 
methods which allow the transfer and stable integration of reporter genes such as green fluorescent protein 
(GFP)  into  the  genomic  DNA  of  cells.    Furthermore,  the  development  of  GFP-expressing  transgenic 
animals  offers  the  opportunity  for  near  limitless  sources  of  labeled  cell  populations  with  sufficient 
stability  of  the  reporter  gene.
5  Such  optical  markers  permitted  the  evaluation  of  labeled  cells  by 
fluorescence microscopy and flow cytometry. However, both of these methods require isolation of the 
cells for analysis and, therefore, sacrifice of the study subjects. This eliminates the possibility of gathering 
important spatiotemporal information about cellular trafficking patterns, the dynamics of cell proliferation 
and the kinetics of cell death within a given animal. This information, however, is essential if one wishes 
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to  reveal  the  cellular  events  leading  to  complex  biological  processes  such  as  tumor  recognition  and 
eradication by immune cells in vivo.
In  vivo  bioluminescence  imaging  (BLI)  has  enabled  the  study  of  tumor  cell  growth  and  offers 
sensitivity as well as a broad dynamic range of quantification. In the presence of oxygen and magnesium 
the  reporter  gene  luciferase  produces  visible  light  from  a  small  molecule  substrate,  luciferin,  in  the 
presence of oxygen and ATP.
6,7 Since visible light penetrates tissues at low levels, cells expressing this 
enzyme  can  be  followed  in  living  animals  by  external  detection  of  the  emitted  light  using  low  light 
imaging systems.
8-11
To extend this approach to syngeneic animal models and to further refine this strategy we have used 
dual  function  reporter  genes  which  code  for a fluorescent marker (either green or yellow fluorescent 
protein, GFP or YFP) for ex vivo cell sorting and a bioluminescent marker for in vivo imaging.  We used 
these  reporter  genes  to  label  the  BALB/c-derived  BCL1  and  A20  B  cell  lymphomas,  and  monitored 
disease growth and metastasis following intravenous (i.v.) injection into syngeneic recipients. The initial 
trafficking  of  the  malignant  cells  through  the  body  as  well  as  organ  specific  homing  and  orthotopic 
expansion  over  time was readily visualized and quantitated. Furthermore, the response of established 
BCL1 and A20 tumors to immune cell therapies and more conventional therapies such as radio- and 
chemotherapy,  was  monitored  in  real  time  and under physiological conditions. In vitro activated and 
expanded effector T cells which have both functional and phenotypic properties of NK cells, termed 
cytokine induced killer (CIK) cells were used in this study.  By tagging the effector cells, we were able to 
non-invasively  monitor  effector  cell  trafficking  patterns  relative  to  tumor  eradication  during 
immunotherapy. The ability to monitor the entire disease course over time revealed tumor-specific escape 
strategies as signals from the lymphoma cells could be detected in the central nervous system following 
high dose irradiation. 
Methods
Animals
Female C57BL/6 (H-2K
b) and BALB/c (H-2K
d) mice were obtained from the breeding facility of the 
Department of Comparative Medicine, Stanford University. All mice were used between 6 and 12 weeks 
of age. Care of all experimental animals was in accordance with institutional guidelines on approved 
protocols.
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Retroviral vectors
The  pGC-gfp/luc  vector    and  the  transfection  procedure  of  Phoenix-E  producer  cells  have  been 
described previously.
12 The pGC-gfp/luc construct was a kind gift of C.G. Fathman, Stanford University. 
The retroviral backbone MND-X-SN was described previously
13 and was a kind gift of D.B. Kohn, USC, 
Los Angeles. The yellow-green luciferase was amplified by PCR from pGL3-Basic (Promega, Madison, 
WI)  using  the  5’  primer 
ATGAATTCAAGCTTATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCT-ATC 
and  the  3’  primer  CTGATCCTTAGGTACCCCTCCACCCAGCCCGCCTGAACCTCCCACGGC-
GATCTTTCCGCCCTTCTTGGCCTTTATGAGGATC. The amplified luciferase cDNA consisting of the 
entire luciferase coding sequences without a stop codon and a linker of 27 nucleotides encoding for 9 
amino acids was inserted into the Hind III and Kpn I sites of the pEYFP-N1 vector (Clontech, Palo Alto, 
CA) in-frame with a cDNA encoding an enhanced yellow-green variant of the green fluorescent protein 
(GFP).  The  full-length  linker  between  luciferase  and  EYFP  is  60  nucleotides 
(GGAGGTTCAGGCGGGCTG-
GGTGGAGGGGTACCGCGGGCCCGGGATCCACCGGTCGCCACC), including 33 from the 5’ of the 
EYFP-N1. The resulting luciferase-EYFP fusion was then cloned into the Hind III and Not I sites of the 
pcDNA3.1  (+)  vector  (Invitrogen,  Carlsbad,  CA).  A  Pme  I  to  Xho  I  fragment  of  luc-EYFP  from 
pcDNA3.1/luc-EYFP was then inserted in between the Hpa I and Xho I sites of the MND-X-SN vector 
and the final construct was named MND-luc/yfp/neo
Transduction of lymphoma cells
BCL1 lymphoma cells were passaged through BALB/c mice, isolated from spleens of tumor bearing 
animals and cryopreserved. Thawed cells were resuspended in RPMI 1640 (Gibco BRL, Gaithersburg, 
MD) containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µM 
2-mercaptoethanol (all Sigma, St. Louis, MO) (cRPMI) and stimulated with 5 µg/ml LPS (Sigma) for 24h. 
Supernatant was removed and cells were cultured in recombinant retroviral supernatant (pGC-gfp/luc) 
supplemented  with  4  µg/ml  polybrene  (Sigma)  and  5  µg/ml  LPS.  48h  post  transduction  cells  were 
analyzed and sorted for GFP expression and 7 x 10
3 GFP
+ cells were injected i.v. into 6-9 wk old BALB/c 
mice. Tumor cells were re-isolated from animals with advanced disease and GFP
+ cells were passaged 
through  4  generations  of  BALB/c  mice  to  guarantee  stable  and  homogeneous  GFP  and  luciferase 
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expression  and  then  through  severe  combined  immunodeficient  (SCID)  mice  to  avoid  lymphocyte 
contamination at the time of cryopreservation.  This line is referred to as BCL1-gfp/luc.
The  A20  cell  line  (ATCC,  Rockville,  MD)  was  stimulated  with  5  µg/ml  LPS  in  cRPMI  and 
retrovirally transduced as described for the BCL1 cell line with the MND-luc/yfp/neo plasmid. Transduced 
cells were cultured in 1 mg/ml G418 (Gibco BRL), outgrowing cells were single cell cloned, a high 
expressing clone was further expanded (A20-luc/yfp/neo) and cryopreserved.
Isolation and transduction of lymphocytes 
Lymphocytes from liver were isolated as described by Eberl et al. 
14 and from spleens as described 
previously.
15 For the generation of transduced CIK cells BALB/c (H-2
d) splenocytes were stimulated in 
cRPMI (3 x 10
6/ml) with 1000 U/ml rmIFN-￿ (R&D Systems, Minneapolis, MN) for 24h, transferred to 
an  anti-CD3  (145-2C11,  BD  Pharmingen,  San  Diego,  CA)  antibody  coated  tissue  culture  flask  and 
stimulated with 300 U/ml rhIL-2 (Chiron, San Francisco, CA). After 36h IL-2 and anti-CD3 stimulation, 5 
x 10
6 cells were resuspended in 2.5 ml retroviral supernatant (pGC-gfp/luc) supplemented with 8 µg/ml 
protamine sulfate (Sigma St. Louis, MO) and 300 U/ml rhIL-2, placed in one well of a 6-well plate and 
centrifuged  for  20  min  at  2300  rpm  and  32°C.  Cells  were  cultured  in  32°C,  5%  CO2  for  8h,  then 
transferred to 37°C, 5% CO2. 24h post transduction 4 ml cRPMI and rhIL-2 were added and 48h post 
transduction cells were sorted by flowcytometry for GFP
+ cells. Cells were expanded for 14-21 days in 
cRPMI containing 300 U/ml rh IL-2 and analyzed by flow cytometry prior to injection. Cells usually were 
20-30% GFP
+ and showed the previously described phenotype 
15.
Bone marrow transplantation of tumor bearing hosts
8-12 wk old female BALB/c mice received 2 x 10
3 BCL1-gfp/luc cells i.v. and were monitored for 
tumor growth by bioluminescence imaging 7 d after tumor inoculation. For bone marrow transplantation, 
tumor bearing hosts were given total body irradiation  (8 Gy) from a 200 Kv X-ray source and injected 
with donor cells via the tail vein within 24h. All mice received 5 x 10
6 BM cells for reconstitution with or 
without T cells or CIK cells as indicated in the text and figures. Mice were kept on antibiotic water 
(sulfomethoxazole/trimethoprim, Schein Pharmaceutical Inc., Port Washington, NY) for the first 28 days. 
Survival and appearance of mice were monitored daily and body weight was measured weekly. 
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In vivo Imaging
Mice were anaesthetized with ketamine (100 mg/kg i.p.) (Fort Dodge, Iowa) and xylazine (10 mg/kg 
i.p.) (Butler, Columbus, Ohio) and an aqueous solution of luciferin (150 mg/kg i.p) (Xenogen Corp., 
Alameda, CA) was injected 5 min prior to imaging. Animals were placed into the light tight chamber of 
the CCD camera system (IVIS, Xenogen Corp.) and a grayscale body surface reference image (digital 
photograph) was taken under weak illumination.
16 After switching off the light source, photons emitted 
from luciferase expressing cells within the animal body and transmitted through the tissue were quantified 
over a defined period of time ranging up to 5 min. using the software program “Living Image” (Xenogen 
Corp.)  as  an  overlay  on  Igor  (Wavemetrics,  Seattle,  WA).  For  anatomical  localization  a pseudocolor 
image  representing  light  intensity  (blue least intense and red most intense) was generated in “Living 
Image” and superimposed over the grayscale reference image. Annotations were added using another 
graphics software package (Canvas 5.0, Deneba, Miami FL). Animals examined for quantification of 
BCL1-gfp/luc tumor growth were imaged from a left lateral position, animals bearing A20-luc/yfp tumors 
were imaged from the ventral position.
Antibodies and Flow Cytometric Analysis (FACS
®)
The following reagents were used for flow cytometric analysis: unconjugated anti-CD16/32 (2.4G2), 
phycoerithrin (PE)-anti - CD19 (1D3), PE-anti - CD45 (30-F11), PE-anti IgM (R6-60.2). Antibodies were 
purchased from BD Pharmingen, San Diego, CA. All staining was performed in PBS/1% calf serum in the 
presence  of  purified  anti-CD16/32  at  saturation  to  block  unspecific  staining  via  FcRII/III.  Propidium 
iodide was added prior to analysis to exclude dead cells. Flow cytometric analyses were performed on 
FACScan or a modified dual laser FACS
® Vantage (Becton Dickinson, San Jose, CA) and data were 
analyzed using FlowJo software (Tree Star Inc., San Carlos, CA). At least 10,000 cells were analyzed. 
Cells analyzed for GFP or YFP expression were examined in the FITC (FL1) channel.
Statistical Methods 
Percent  signal  reduction  following  chemo-  or  irradiation  therapy  was  calculated  according  to  the 
formula: % signal reduction = 100 – [signal intensity d4 post treatment – background signal intensity] x 
100 / [pre-treatment signal intensity – background signal intensity]. Background signal was determined by 
imaging 10 sex and age matched BALB/c animals that did not receive luciferase transduced cells. Data are 
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reported  as  mean  and  range.  Differences  in  survival  of  groups  of  hosts  given  BM  transplants  were 
analyzed using the log-rank test.
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Results
Spatiotemporal tracking of BCL1-gfp/luc and A20-luc/yfp B cell lymphoma cells in vivo
The BALB/c-derived B cell lymphoma cell line BCL1 was chosen as one of the first model tumors 
because of its known homing pattern to liver and spleen in recipient BALB/c animals.
17,18 Since BCL1
cells cannot be maintained long term in culture, a retroviral transduction system was used for the delivery 
of a gfp/luc fusion gene. Cells were transduced 24h after thawing and then sorted by FACS for GFP 
expression. GFP
+ BCL1 cells were passaged four times through syngeneic recipients and finally through 
BALB/c  SCID  mice  before  cryopreservation.  The  resulting  BCL1-gfp/luc  tumor  cells  showed  a 
homogenous  expression  of  GFP  (Figure  1A).  The  time  course  of  engraftment  and  organ  specific 
expansion of 7 x 10
3 BCL1-gfp/luc cells after i.v. injection into BALB/c animals is shown in Figure 1B. 
All  recipients  showed  tumor  engraftment.  Shortly  after  injection,  a  bioluminescent  signal  could  be 
detected over the lungs. Repetitive imaging of individual animals on the following days demonstrated 
tumor cell homing to the spleen by day 5 followed by a logarithmic growth phase in spleen and liver, as 
quantitated at weekly intervals by measuring the amount of light emitted from the body of the animals 
over  a  5  min  integration  time  (Figure  1C).    Despite  this  progressive  tumor  growth  that  was  readily 
demonstrable by BLI, the animals appeared normal until several weeks later when disease manifestation 
characterized  by  ascites  and  wasting  became  evident.  At  that  stage,  BLI  revealed  massive 
hepatosplenomegaly  with  metastasis  to  the  lungs  (Figure  1B)  as  well  as  the  BM  and  a  leukemic 
distribution of tumor cells (not visible in Figure 1B since sensitivity of detection was adjusted for optimal 
display of organ infiltration). At the same time, tumor cells within the spleen could also be visualized by 
fluorescence microscopy revealing diffuse infiltration and effacement of the splenic architecture (data not 
shown).
Similar studies were performed in a second tumor model after retroviral transduction of the BALB/c-
derived A20 lymphoma/leukemia cell line with a vector delivering a luc/yfp fusion construct. Transduced 
A20-luc/yfp cells (2 x 10
4) were injected i.v. into sublethally (4 Gy) irradiated Balb/c recipient mice.  
Within 7 days, homing of the tumor cells to the bone marrow cavity was readily apparent with signal over 
the bilateral humeri and femurs, as well as sternum and vertebrae (Figure 2A).  Again, tumor growth in 
the bone marrow cavity could be quantitatively assessed by serial determination of the amount of light 
emitted  from  individual  animals,  which  revealed  a  growth  lag  phase  of  5-7  days,  followed  by  a 
logarithmic growth period until day 21 (Figure 2B).  FACS analysis on day 21 confirmed the bone marrow 
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infiltration and showed that over 60% of the isolated BM cells were indeed CD19
+ YFP
+ tumor cells 
(Figure 2C).  
To address the question to what extent light emission quantified by BLI accurately reflects the total 
tumor burden of an animal, a series of 15 BCL1-gfp/luc tumor bearing animals at various stages of disease 
were  first  evaluated  by  BLI,  then  sacrificed  and  the  percentages  of  GFP
+  cells  in  liver  and  spleen 
determined by FACS analysis. Since BCL1 tumor cells are found almost exclusively in these two organs 
until late in the disease course, the total number of splenocytes and hepatic lymphocytes was multiplied by 
the percentage of GFP
+ cells to approximate the total number of BCL1 tumor cells. A linear correlation 
between the number of tumor cells as determined by FACS analysis and the BLI signal intensity was 
obtained over at least 4 logs of tumor burden (r = 0.989; Figure 3A). The lowest level of GFP
+ tumor cells 
detectable by FACS in the spleen was 2.3 x 10
4. BLI, however, was significantly more sensitive and we 
could reliably detect labeled tumor cells within the spleen even before they were detectable by FACS. 
Representative FACS patterns of liver and spleen from animals with either high (top panels) or low tumor 
burden (bottom panels) are shown in Figure 3B.
Response to chemo- and radiation therapy revealed in vivo in an orthotopic tumor model
To evaluate the response of an established B cell lymphoma to therapeutic interventions in vivo and in 
real time, BALB/c recipients were injected with 2 x 10
3 BCL1-gfp/luc tumor cells and their orthotopic 
tumor  growth  was  assessed  by  BLI  after  14  days.  As  expected,  animals  within  a  control  group  that 
received no further treatment showed a continuous increase in their tumor signal (Figure 4A). In contrast, 
treatment of a second group of animals (n = 5) with cyclophosphamide (2 x 40 mg/kg i.p. in a 24 h 
interval) resulted in a substantial reduction in tumor burden (mean: 95.7%; range: 95.0% - 96.3%) within 
the next 4 days. This was followed by a relapse 1-2 weeks after treatment and exponential growth of the 
tumor over the remaining observation time of 5 weeks (Figure 4B).  Similarly, tumor response to radiation 
therapy was assessed by exposing tumor bearing animals to 8 Gy total body irradiation followed one day 
later by a rescue of the animal with syngeneic BM cells. As in the control group, tumor engraftment and 
growth was observed in all animals 14 days after injection (n = 4). Four days following irradiation there 
was a significant (mean: 96.2%; range: 94.8% - 97.5%) reduction in tumor signal (Figure 4C).  Again, 
however, all animals relapsed within the next 14-21 days.  Low dose irradiation with 2 Gy had no impact 
on tumor growth (data not shown).  
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In vivo monitoring of tumor eradication by in vitro activated and expanded effector T cells
To explore the impact of an adoptive cellular therapy after allogeneic BMT on disease burden and 
control of minimal residual disease (MRD) we utilized ex vivo activated CD8
+ NK-T cells. These cells 
can  be  readily  expanded  from  splenocytes  or  peripheral  blood  lymphocytes  through  culture  with 
interferon-￿￿(IFN-￿),  anti-CD3  monoclonal  antibodies  and  interleukin-2  (IL-2).
19-21  This  cytotoxic  cell 
population, termed cytokine induced killer (CIK) cells, shares functional and phenotypic properties of 
both T and NK cells and recognizes a broad array of both syngeneic and allogeneic tumor targets. In 
addition, CIK cells have a marked reduction in their ability to cause GVHD at least in part due to the 
production of high levels of IFN-￿
15. To examine the effects of CIK cells on BCL1-gfp/luc lymphoma 
growth after allogeneic BMT we established the lymphoma in recipient BALB/c mice by i.v. injection of 2 
x  10
3  tumor  cells  and  transplanted  these  animals  8  days  after  tumor  cell  inoculation  (24h  after 
myeloablative (8 Gy) irradiation). Groups of animals were treated either with 5 x 10
6 BM cells from 
C57BL/6 donor animals alone or BM plus 2.5 x 10
6 C57BL/6 splenocytes or BM plus 2.5 x 10
6 CIK cells 
expanded from C57BL/6 mice.  Disease burden was assessed by BLI prior to irradiation, two days post 
irradiation and at weekly intervals thereafter. All animals demonstrated an increase in tumor signal during 
the first 7 days after tumor inoculation, followed by a reduction of tumor load after irradiation. Using BLI 
a  quantitative  evaluation  of  tumor  burden  and  response  to  therapy  could  be  evaluated  in  individual 
animals, a unique feature of this imaging strategy. All animals that received only allogeneic BM cells 
eventually relapsed within 14-35 days (Figure 5A) and succumbed to disease several weeks later (Figure 
5D). However, time and kinetics of tumor relapse showed a higher variability as compared to animals 
treated with cyclophosphamide or syngeneic BMT (Figure 3), suggesting that alloreactive mechanisms 
have some influence on tumor relapse kinetics but that these effects are not sufficient for effective tumor 
control. All animals treated with 2.5 x 10
6 splenocytes died rapidly from acute GVHD prior to an eventual 
disease relapse after irradiation (Figure 5B and D).  In marked contrast, animals treated with 2.5 x 10
6
CIK cells maintained control of disease burden after BMT throughout the observation period of 120 days 
without showing significant signs of GVHD (Figures 5C and 5D; P < 0.0001). 
Unexpectedly, BLI revealed a dramatic change in tumor location at early time points in animals treated 
with high dose irradiation and BMT. Following irradiation, a sustained reduction in the splenic signal was 
clearly demonstrable accompanied by the emergence of a tumor signal projecting to the central nervous 
system (CNS) (Figure 5E). This redistribution was observed beginning 1 week after irradiation and was 
uniformly seen in animals surviving beyond that time point irrespective of the treatment regimen (BMT 
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+/- CIK cells). The signal from these sites did not increase over time, suggesting that no significant tumor 
cell expansion occurred and no neurologic deficit was noted in these animals. In the A20-yfp/luc tumor 
model,  however,  animals  experienced  an  irradiation  dose  dependent  meningeal  tumor  infiltration  and 
suffered hind limb paralysis 15-25 following BMT caused by tumor compression of the spinal cord. While 
low dose irradiation with 2 Gy did not lead to paralysis (n = 7), paralysis was observed in 66% of animals 
that received 4 Gy total body irradiation (8 out of 12) and in all animals treated with 6 Gy (n = 7) or 8 Gy 
and rescued by a syngeneic or allogeneic BMT (n > 30). BLI performed ex vivo on freshly isolated spinal 
cords as well as histopathological evaluation revealed meningeal disease with tumor studding of the spinal 
cord (data not shown). 
Tracking of effector T cells in tumor bearing mice
Since lymphoma cells and CIK cells migrate to the same organs following i.v. injection, we examined 
effector cell migration to an ectopic tumor site in a syngeneic tumor model. For this purpose, BALB/c 
splenocytes were transduced with the gfp/luc retrovirus and expanded under CIK culture conditions.  Five 
x 10
6 CIK cells (25% GFP
+) were injected i.v. into syngeneic Balb/c animals bearing macroscopic tumors 
generated by s.c. injection of 1 x 10
7 A20-lymphoma cells 10 days prior to treatment (Figure 6). The 
injection site was shaved to allow for external tumor visualization.  Thirty minutes after i.v. injection, 
Luc
+ CIK cells could be detected by BLI in the lungs of the animals. This was followed by a more general 
distribution of the cells to other sites within the body, such as liver and spleen, within the next 16 hrs. By 
72h, a clearly defined population of labeled effector cells infiltrated the subcutaneous tumor on the flank 
of the animal. Luc-expressing CIK cells remained detectable by BLI at the tumor site for an additional 
period of 9 days over which time the tumor mass completely regressed. Five out of 6 animals treated with 
expanded CIK cells (in two separate experiments) did not show any signs of tumor relapse throughout the 
observation period of 6 months. In contrast, all untreated animals developed large tumor masses and were 
sacrificed within 12 weeks due to severe progressive disease (n = 6).  These studies demonstrate that BLI 
can  be  readily  used  to  assess  the  anti-tumor  activity  of  expanded  CD8
+  NK-T  cells  in  vivo  in  both 
syngeneic and allogeneic animal models. 
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Discussion
Animal models of leukemia and lymphoma are critically important for both the study of the basic 
biology of these malignancies as well as for the development of improved therapeutic interventions. The 
examination of complex biological processes such as tumor growth, metastasis and response to therapy 
requires animal models capable of detecting small numbers of cells, non-invasively and quantitatively. We 
previously  described  a  new  bioluminescence  based  imaging  technology  allowing  the  non-invasive 
detection of human tumor cells in living severe combined immunodeficient (SCID) animals with high 
sensitivity.
8,11 In these initial experiments, the human cervical carcinoma cell line HeLa-luc was engrafted 
into SCID animals for proof of principle. However, neither tumor cell nor effector cell trafficking could 
reliably be evaluated in these xenogenic systems. Here, we describe two tumor models allowing for the in 
vivo  examination  of  leukemia  and  lymphoma  cell  trafficking  and  proliferation  in  real  time.  For  this 
purpose,  we  utilized  dual  function  reporter  genes  to  link  the  powerful  in  vivo  analyses  via 
bioluminescence imaging (BLI) to the cell discriminating ex vivo assays that employ flow cytometry.
22
The fluorescent function of the gene fusion allows for the isolation and recovery of transduced cells either 
before,  or  after, the cell distribution patterns are revealed in living animals using the bioluminescent 
component  of  the  dual  function  reporter  gene.
23  The  results  presented  in  this  report  demonstrate  the 
remarkable  sensitivity  of  bioluminescence  based  imaging  strategies  and  the  ability  to  quantitatively 
measure tumor burden over the entire spectrum of disease from minimal to massive tumor burden in 
individual animals. 
This approach has several advantages over conventional tumor models: the sensitivity of cell detection 
in vivo is surprisingly high and exceeds even the sensitivity of detection by flow cytometry ex vivo.  As 
few as 7 x 10
3 cells are detectable in the lungs early after injection, 2 - 2.5 x 10
4 cells within liver or 
spleen and as few as 1 x 10
4 tumor cells within the BM of a femur give rise to a sufficient signal to be 
detected externally. In other experiments using cells with even higher luciferase expression as few as 100 
cells can be reliably detected in the peritoneal cavity of living animals. Since cells are detectable even 
from deep within tissues, tumor cell trafficking, engraftment in different organs and metastasis could be 
visualized without perturbing intact organ systems. Given that the amount of light emitted from tumor 
bearing animals can be quantified externally at serial time points, tumor growth kinetics can be evaluated 
non-invasively. Using the fluorescent component of the dual function reporter genes for the re-isolation of 
lymphoma cells from tumor bearing mice reveals, that the signal intensity detected externally correlates 
highly with tumor load (r = 0.989). This high correlation allows for extrapolation of the in vivo tumor cell 
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doubling  time  and  verifies,  that  the  signal  intensity  reflects  tumor  load  reliably  to  allow  for  the 
quantitative  evaluation  of  the  effects  of  cytostatic  and  cytotoxic  therapies.  As  examples,  response  to 
chemo- and radiation therapies were studied confirming that even minimal residual disease is detectable 
and that location, timing and kinetics of tumor relapse could be determined. Using this technology it is 
now possible to study early events in tumor development long before any clinical signs of disease are 
evident as well as the efficiency of therapeutic interventions in minimal disease stages. These new tools 
will improve our understanding of tumor biology, tumor immunology and facilitate drug discovery and 
evaluation.
Thusfar,  we  have  used  tumor  cell  lines  to  examine  the  effects  of  chemotherapy,  radiation  and 
immunotherapy. The inclusion of bioluminescent reporter genes into inducible transgenes for the targeted 
overexpression  of  oncogenes  and/or  tumor  suppressor  gene  mutant  systems  could  be  used  in 
‘spontaneous’  models  of  malignancy  to  facilitate  the  examination  of  early  molecular  events  in 
carcinogenesis.
24 Recently, Vooijs et al reported the successful integration of bioluminescent reporter 
genes in such a model system using retinoblastoma (Rb) mutant animals for the study of pituitary gland 
tumor  development.
25  Similar  systems  for  the  study  of  “spontaneous”  models  of  hematopoietic 
malignancy are currently under development. Given the good sensitivity of cell detection from within the 
bone  marrow,  such  approaches  will  greatly  facilitate  the  examination  of  early  molecular  and cellular 
events in leukemia development and hematopoietic stem cell biology. The transduction of non-malignant 
hematopoietic stem cells with optical reporter genes will furthermore greatly facilitate the examination of 
trafficking and expansion of precursor cells after BMT. 
We have utilized these bioluminescent tumor models to assess the anti-lymphoma effect of adoptive 
cellular immunotherapy after allogeneic BMT. To do this, we infused ex vivo expanded CD8
+ T cells, 
which share functional and phenotypic properties with NK cells (CIK cells). CIK cells are capable of 
protecting animals from an otherwise lethal challenge of BCL1 tumor cells utilizing either syngeneic or 
allogeneic effector cells
15. As described previously, CIK cells cause much less GVHD than splenocytes 
when transplanted across major histocompatibility barriers in part due to the production of IFN-￿ since 
CIK cells derived from animals incapable of producing this cytokine result in rapid lethal GVHD.
15 Here 
we show, that CIK cells are capable of inhibiting BCL1-gfp/luc relapse as assessed serially by BLI without 
causing GVHD. The infusion of freshly isolated splenocytes resulted in acute GVHD and rapid animal 
death even before reaching the time of relapse of BM control groups. The effects of CIK cells appeared to 
occur rapidly following infusion and prevented the early growth of BCL1-gfp/luc. The strategy of utilizing 
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CIK cells which have a rapid onset of action due to prior in vitro activation may be particularly valuable in 
disease conditions where early relapse is a high risk. Following non-myeloablative conditioning regimens 
CIK treatment may control disease burden prior to the delayed onset of GVL effects generated by immune 
cells derived from the transplanted donor BM. Such strategies are currently under investigation. In our 
tumor models, BLI revealed an infiltration of the CNS by lymphoma cells following high dose whole 
body irradiation and BMT. This unexpected finding demonstrates that unique trafficking patterns can 
result  following  therapeutic  interventions  that  can  only  be  revealed  by  sensitive  in  vivo  imaging 
techniques.
26 Since the CNS is a frequent sanctuary site in hematological malignancies this finding was of 
particular interest. CNS relapse has been observed following transplantation, even in clinical situations 
where this may not be predicted (e.g. in patients with multiple myeloma). Therefore, evaluation of the 
impact of different preparative regimens with respect to dose of irradiation and impact of chemotherapy 
on  CNS  infiltration  with  malignant  cells  can  be  directly  studied  with  BLI  and  could  have  important 
ramifications in clinical bone marrow transplantation.  
In  a  second  tumor  therapy  model  we  directly  evaluated  the  in  vivo  fate  of  CIK  cells  following 
retroviral marking with GFP and Luc. Labeled CIK cells were initially visualized over the lungs following 
i.v. injection. Within 24 hours they migrated to extra-pulmonic sites and by 3 days the infiltration of a 
subcutaneous lymphoma could be directly visualized. The effector cells persisted at this location for at 
least 9 days resulting in tumor eradication. These results are in agreement with our in vitro observations 
that  cell  contact  is  necessary  for  antitumor  cytotoxicity.
21  These  studies  further  demonstrate  that  the 
biological effects of CIK cells occur rapidly and that the cells persist in vivo for approximately two weeks. 
It should be noted that these studies were performed without the administration of additional cytokines 
such as IL-2 which may be a unique advantage of CIK cells over other preparations of NK-like cells such 
as LAK cells.
19 For CIK cells, we have previously demonstrated the critical role of perforin for their tumor 
eradication in vivo, whereas Fas-L appears to be less important.
27 The future evaluation of additional 
effector and target recognition molecules and their differential use by different lymphocyte populations 
may provide novel insights into the role of these gene products in lymphocyte biology and tumor immune 
surveillance. 
The use of BLI for the evaluation of adoptively transferred cells allows the study of their fate in vivo
throughout the entire course of immunotherapy. Following i.v. administration their migration through 
lungs and internal organs like liver, spleen and lymph nodes is visualized as well as their arrival at tumor 
sites and disease eradication. The goal of ongoing studies is the evaluation of key molecular mechanisms 
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required for completion of various steps in this process. Cellular migration in and out of organs through 
endothelial barriers and into tissues is well orchestrated by adhesion molecules and chemokines.
28 The use 
of knock-out animals lacking these molecules as recipients or cell donors will reveal some of the main 
mechanisms involved in this process. In our studies, only a subset of injected CIK cells are found at the 
tumor  site.  The  re-isolation  and  characterization  of  the  cells  infiltrating  the  tumor  tissue  and  their 
comparison to cells migrating to other sites is another approach currently under investigation for the 
identification  of  molecules  involved.    A  limitation  of  this  strategy  is  the  relatively  low  transduction 
efficiency of retroviral vectors for primary lymphocyte populations and the risk of gene silencing.
29,30
Transduction efficiencies of 10–30% are adequate to image the transduced lymphocyte populations due to 
the remarkable sensitivity of BLI. However, higher levels of gene marking will significantly facilitate cell 
recovery  from  the  animals.    Other  approaches,  such  as  the  use  of  lentiviral  vector  systems  and  the 
generation  of  transgenic  animals  with  constitutive  or  inducible  expression  of  bioluminescent  reporter 
genes will be important in overcoming these limitations. One concern is the possibility that the repoter 
genes could be immunogenic, as previously described for GFP.
31,32 In our experiments, however, we 
could not detect any enhanced immune recognition of BCL1-gfp/luc cells and the observation period for 
transduced CIK cells might have been too short for an immune response to occur.
In this study we further refined BLI  as a powerful tool for the study of neoplastic disease by using the 
dual  function  reporter  genes.  This  non-invasive,  highly  sensitive  and  quantitative  approach  is  ideally 
suited  for  evaluating  complex  biological  processes in  vivo  such  as  lymphocyte  trafficking  and  tumor 
eradication. These studies allowed, for the first time, real-time visualization of GVL activity. Utilizing 
BLI  all  of  the  steps  required  for  effective  adoptive  immunotherapy  following  i.v.  injection  of  cells 
including  migration  through  the  lungs,  spleen  and  infiltration  of tumor tissues can be visualized and 
studied. Further evaluation of the cells which effectively localize to tumor tissue is a major advantage of 
this approach and the goal of future studies.
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Figure 1: In vivo imaging of BCL1 lymphoma. (A) BCL1 lymphoma cells were transduced with the 
pGC-gfp/luc fusion construct, sorted for GFP and injected intravenously (i.v.) into syngeneic BALB/c 
mice. GFP
+  cells were passaged 4 times through BALB/c animals and finally through SCID mice to avoid 
lymphocyte contamination at time of cryoconservation. The final BCL1-gfp/luc cells are CD19
+ and show 
a homogeneous GFP expression. (B) 7 x 10
3 BCL1-gfp/luc cells were injected i.v. into syngeneic BALB/c 
mice. Three h post injection (d 0) a bioluminescent signal (ventral and lateral views) was detectable from 
the lungs (first two images) and after 4-5 days tumor engraftment in liver and spleen could be visualized 
(second two images). Tumor growth leading to massive hepato-splenomegaly could be followed over the 
next 5 weeks (third set of images) and an infiltration of lungs and lymph nodes was observed in final 
disease stages (5 wks; final image). The scale to the left of the images describes the color map for the 
photon count. (C) Quantification of tumor growth by measuring light emission from BALB/c mice after 
i.v. injection of 2 x 10
3 BCL1-gfp/luc cells (filled circle, n = 5) in comparison to a disease free control 
animal (open square).
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Figure 2: Visualization of leukemic bone marrow infiltration by BLI. (A) Leukemic infiltration of the 
BM of sublethally irradiated BALB/c mice as revealed by whole body BLI one week after intravenous 
injection of 2 x 10
4 A20-luc/yfp cells into sublethally irradiated BALB/c mice (4 Gy). The scale to the left 
of  the  images  describes  the  color  map  for  the  photon  count. (B)  Tumor  expansion  as  quantified  by 
measuring the photon counts of individual animals (n = 4) emitted at the time points indicated. (C) FACS 
analysis of BM cells from the femur 21 d post tumor inoculation revealed that 61% of the BM cells were 
CD19
+, YFP
+ tumor cells.
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Figure 3: Correlation of bioluminescent signal intensity with tumor burden. (A) Linear correlation (r 
= 0.989) between bioluminescent signal intensity determined in vivo and tumor burden as determined by 
FACS analysis of isolated cells from the liver and spleen of tumor bearing animals (n = 15) 1 – 4 wks 
after  intravenous  injection  of  2  x  10
3  BCL1-gfp/luc  cells.  (B)  FACS  plots  represent  analyses  of  the 
hematopoietic cell fraction (CD45
+) of liver and spleen from an animal with high (filled square in (A), top 
row)  and one with low tumor load (filled triangle in (A), lower row). Numbers represent the percentage of 
cells within quadrants.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 24
Figure  4:  Tumor  regression  in  response  to  chemo-  and  irradiation  therapy.  BALB/c  mice  were 
engrafted with 2 x 10
3 BCL1-gfp/luc lymphoma cells and tumor growth was quantified by BLI 14 d post 
tumor inoculation. Groups of animals received either (A) no further treatment (n = 3), (B) 2 x 40 mg/kg 
cyclophosphamide i.p. within 24 h (n = 5), or (C) total body irradiation with 8 Gy followed 24 h later by a 
syngeneic bone marrow transplantation (n = 4). Tumor growth, regression and relapse were determined by 
BLI 2 d and 4 d post treatment and in weekly intervals thereafter.
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Figure 5: Inhibition of tumor relapse by CIK cells after allogeneic bone marrow transplantation. 
BALB/c mice (H-2
d) received 2 x 10
3 BCL1-gfp/luc lymphoma cells i.v. and tumor engraftment was 
monitored and quantified by BLI on d 7 as described in “Materials and Methods”. Following BLI, animals 
were lethally irradiated (8 Gy) and transplanted within 24 h with 5 x 10
6 whole BM cells from C57BL/6 
animals (H-2
b). Treatment groups received either (A) BM alone (n = 11), (B) BM + 2.5 x 10
6 splenocytes 
(n = 9), or (C) BM + 2.5 x 10
6 CIK cells (n = 13). Tumor regression following irradiation was determined 
2  or  3  d  after  irradiation  and  animals  were  monitored  by  BLI  for  tumor  relapse  in  weekly  intervals 
thereafter (A-C). On the x-axes are days after tumor cell injection. The y-axes are relative light emission 
from individual animals over a 5 min integration time. (D) Survival of animals from treatment groups A 
(open squares), B (open triangles) and C (open circles); on the x-axis are days after tumor cell injection. 
On the y-axis is the proportion of recipients surviving. (P < 0.0001 between all treatment groups). (E) 
Tumor distribution pattern of one representative animal prior to irradiation (d7), 2 d post irradiation (d9) 
and 9 d post irradiation (d16). 
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Figure 6: Trafficking of CIK cells. BALB/c splenocytes were retrovirally transduced with the pGC-
gfp/luc vector, FACS sorted and expanded under CIK culture conditions as described in "Material and 
Methods".  Transduced  CIK  cells  were  injected  intravenously  (i.v.)  into  syngeneic  animals  bearing  a 
macroscopically visible A20-lymphoma sucutaneously (s.c.) (n = 6 in two separate experiments). Shown 
in the figure is the repetitive imaging of one representative animal. d 0: early localization of CIK cells to 
the lungs; d 1: Distribution to other sites including liver and spleen; d 3: preferential infiltration of s.c. 
tumor site (shaved area lower right quadrant and shaved control area in the middle of the back of the 
animal);  d  12:  regression  of  tumor  and  minimal  signal  from  remaining  CIK  cells.  For  d3  and  d12 
tangential  photographs  (greyscale)  are  shown  for  a  better  tumor  localization  and  the  bioluminescent 
overlay (bioluminescence) for CIK cell localization.
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